| WB | 1/500 - 1/2000 | Human,Rat,Monkey |
| IF | 咨询技术 | Human,Rat,Monkey |
| IHC | 咨询技术 | Human,Rat,Monkey |
| ICC | 1/200 - 1/1000 | Human,Rat,Monkey |
| FCM | 1/200 - 1/400 | Human,Rat,Monkey |
| Elisa | 1/10000 | Human,Rat,Monkey |
| Aliases | DTD; QR1; DHQU; DIA4; NMOR1; NMORI |
| Entrez GeneID | 1728 |
| clone | 1A11 |
| WB Predicted band size | 31kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat,Monkey |
| Immunogen | Purified recombinant fragment of human NQO1 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于NQO1抗体的3-4篇参考文献示例(注：文献信息为虚构示例，仅用于演示格式)：
---
1. **文献名称**：*NQO1 overexpression in human tumors: A potential biomarker for chemoresistance*
**作者**：Ross D., Siegel D.
**摘要**：本研究通过Western blot和免疫组化分析，利用特异性NQO1抗体检测多种肿瘤组织中NQO1蛋白的表达水平，发现其过表达与化疗耐药性显著相关，提示NQO1可作为临床预后标志物。
2. **文献名称**：*Regulation and function of NQO1 in cellular antioxidant defense*
**作者**：Siegel D., Ross D.
**摘要**：文章探讨NQO1的转录调控机制及其在氧化应激中的作用，通过免疫荧光和ELISA实验(使用小鼠来源的NQO1单克隆抗体)，验证了NQO1在保护细胞免受醌类毒素损伤中的功能。
3. **文献名称**：*NQO1 polymorphisms and enzyme activity: Correlations in human populations*
**作者**：Jaiswal A.K.
**摘要**：研究分析了NQO1基因多态性(如C609T突变)与酶活性的关系，利用多克隆NQO1抗体对患者组织样本进行免疫印迹分析，发现特定突变导致蛋白稳定性下降，影响抗氧化能力。
4. **文献名称**：*Validation of NQO1-specific antibodies for immunohistochemical applications*
**作者**：Asher G., Tsvetkov P.
**摘要**：该研究系统评估了多种市售NQO1抗体的特异性及灵敏度，通过敲除细胞模型和肿瘤切片验证，推荐了适用于不同实验场景(如流式细胞术、病理切片)的优质抗体。
---
**注意**：以上文献为示例，实际引用时请通过PubMed、Google Scholar等平台检索真实存在的文献并核对信息。
The NAD(P)H:quinone oxidoreductase 1 (NQO1) antibody is a crucial tool for studying the NQO1 enzyme, a cytosolic flavoprotein involved in cellular antioxidant defense and xenobiotic metabolism. NQO1 catalyzes the two-electron reduction of quinones to hydroquinones, preventing redox cycling and oxidative stress. It is regulated by the Nrf2-Keap1 pathway and exhibits both catalytic and non-enzymatic roles, including stabilization of tumor suppressors like p53.
NQO1 is overexpressed in various cancers (e.g., lung, pancreatic, breast) and is associated with poor prognosis, making it a potential therapeutic target and biomarker. Its genetic polymorphism (C609T) results in reduced enzyme activity, linked to increased disease susceptibility. NQO1 antibodies are widely used in techniques like Western blot, immunohistochemistry, and immunofluorescence to quantify protein expression, assess subcellular localization, and correlate levels with clinical outcomes.
Commercial NQO1 antibodies target specific epitopes, with clones like A180 and H6 commonly validated for human samples. Researchers rely on these antibodies to investigate NQO1's role in cancer progression, chemoresistance, and response to NQO1-targeted therapies (e.g., β-lapachon). Validation via knockout controls or enzymatic activity assays is critical due to potential cross-reactivity with homologous proteins. Understanding NQO1's dual roles in cytoprotection and pathology remains central to redox biology and precision medicine.
×
